Skip to Content

Cytovene (ganciclovir) Disease Interactions

There are 3 disease interactions with Cytovene (ganciclovir):


Ganciclovir (Includes Cytovene) ↔ Bone Marrow Suppression

Severe Potential Hazard, High plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

The use of ganciclovir is commonly associated with bone marrow toxicity. Neutropenia, anemia and thrombocytopenia have been reported. Therapy with ganciclovir should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Routine blood counts are recommended, and dosing adjusted or discontinued accordingly. Ganciclovir should not be used in patients with an absolute neutrophil count < 500/mcL or a platelet count < 25,000/mcL. Some neutropenic patients requiring ganciclovir may be candidates for granulocyte colony stimulating factor.


  1. "Product Information. Cytovene (ganciclovir)." Genentech, South San Francisco, CA.
  2. SOCA Reseach Group, et al "Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis." N Engl J Med 326 (1992): 213-20
  3. Faulds D, Heel RC "Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections." Drugs 39 (1990): 597-638
  4. Sulecki M, Rosenfeld CS, Przepiorka D, et al "Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF." Am J Med 90 (1991): 401-2
View all 4 references

Ganciclovir (Includes Cytovene) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Ganciclovir is primarily eliminated by the kidney. Patients with renal impairment may be at greater risk for toxicity from ganciclovir due to decreased drug clearance. Therapy with ganciclovir should be administered cautiously in these patients at reduced dosages. Serum creatinine values should be monitored frequently, and the dosing further adjusted or discontinued accordingly.


  1. Lake KD, Fletcher CV, Love KR, et al "Ganciclovir pharmacokinetics during renal impairment." Antimicrob Agents Chemother 32 (1988): 1899-900
  2. "Product Information. Cytovene (ganciclovir)." Genentech, South San Francisco, CA.
  3. Sommadossi JP, Bevan R, Ling T, et al "Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function." Rev Infect Dis 10 (1988): s507-14

Ganciclovir (Includes Cytovene) ↔ Hemodialysis

Moderate Potential Hazard, High plausibility

Applies to: hemodialysis

Ganciclovir is substantially removed by hemodialysis. Plasma levels of ganciclovir have been shown to reduce by 50% following hemodialysis. Ganciclovir should be administered on non-dialysis days or following dialysis sessions.


  1. "Product Information. Cytovene (ganciclovir)." Genentech, South San Francisco, CA.
  2. Swan SK, Munar MY, Wigger MA, Bennett WM "Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis." Am J Kidney Dis 17 (1991): 69-72

Cytovene (ganciclovir) drug Interactions

There are 208 drug interactions with Cytovene (ganciclovir)

Cytovene (ganciclovir) alcohol/food Interactions

There is 1 alcohol/food interaction with Cytovene (ganciclovir)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.